好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Post Covid-19 Neurological Impairment Effects on Activities of Daily Living: Patient Perspectives from a Remote Patient Monitoring Program
Infectious Disease
P4 - Poster Session 4 (8:00 AM-9:00 AM)
4-002

Here, we emphasize the debilitating effects on daily life of post covid cognitive impairment, from the patient perspective. In this, we will gain deeper insight into the post-acute illness phase of COVID-19 to formulate more compassionate, supportive, and efficacious treatment protocols.


Post Covid-19 acute infection neurological impairment has been shown to be a long term effect of the disease. 18 months after the onset of the COVID-19 pandemic, with over 230 million cases worldwide, it has never been more critical to understand such long term effects. 


46 Patients in a COVID-19 Remote Patient Monitoring Program (Precision Recovery: Mount Sinai Health System) were interviewed regarding their experience with COVID-19. Patients were asked about their experiences navigating COVID-19 diagnoses, the health care system, and their recovery process. Patients were not pointedly asked about cognitive impairment post covid and all mentions were unprompted. References to post-cognitive impairment were analyzed for statistical and qualitative significance. 


20/46 (43%) of patients reported cognitive impairment after the acute phase of their covid illness. 8/20 of these individuals (40%) were self identified long-haul covid patients. Patients identified three patterns of impairment: (1) memory; (2) attention; and (3) mental stamina. These new cognitive deficits impacted daily life in four key ways: (1) failure to adhere to daily responsibilities; (2) necessitated decrease in employment responsibilities; (3) insecurity in social interactions; and (4) development of coping strategies. 


Post covid cognitive impairment significantly impacted both acute and long-haul covid patients. It is therefore critical to acknowledge this potential long-term effect as an outcome for anyone who experiences Covid-19 for improved understanding of patient illness experience and development of covid-19 treatment post-acute infection. 


Authors/Disclosures
Emma Reford
PRESENTER
Ms. Reford has nothing to disclose.
No disclosure on file
Natalia Romano Spica Ms. Romano Spica has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Christopher P. Kellner, MD (Mount Sinai Health System) Dr. Kellner has stock in METIS Innovative. Dr. Kellner has stock in Precision Recovery. Dr. Kellner has stock in Synchron. Dr. Kellner has stock in Fluid BioMed. Dr. Kellner has stock in Proprio. Dr. Kellner has stock in Von Vascular. Dr. Kellner has stock in E8. Dr. Kellner has stock in Borvo. Dr. Kellner has stock in Phantom Neuro. Dr. Kellner has stock in Radical. Dr. Kellner has stock in Reach Neuro. Dr. Kellner has stock in Aurenar. The institution of Dr. Kellner has received research support from Integra. The institution of Dr. Kellner has received research support from Penumbra. The institution of Dr. Kellner has received research support from Viz.AI. The institution of Dr. Kellner has received research support from ICE Neurosystems. The institution of Dr. Kellner has received research support from Irras. The institution of Dr. Kellner has received research support from Microtransponder. The institution of Dr. Kellner has received research support from Medtronic. The institution of Dr. Kellner has received research support from Longeviti. The institution of Dr. Kellner has received research support from Endostream. The institution of Dr. Kellner has received research support from CVAID.